Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Agent for prevention and treatment of acute renal failure

A technology for acute renal failure and therapeutic agent, which is applied in the field of prevention and therapeutic agent for acute renal failure, and can solve problems such as no report of application effect.

Inactive Publication Date: 2008-12-17
SANWAKAGUKU KENKYUSHO CO LTD +1
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the application effect of hydantoin derivatives for the prevention and treatment of acute renal failure has not yet been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for prevention and treatment of acute renal failure
  • Agent for prevention and treatment of acute renal failure
  • Agent for prevention and treatment of acute renal failure

Examples

Experimental program
Comparison scheme
Effect test

experiment Embodiment 1

[0030] The effect of fidarestat on renal injury in ischemia-reperfusion mice

[0031] 1. Materials and methods for pharmacological experiments

[0032] Male C57BL / 6 mice (Wild) between sixteen and twenty weeks old were used in the experiment. The mice were divided into 4 groups, which were designated as sham operation group (normal control group), ischemic operation group (ischemia reperfusion control group), ischemia operation + fidarestat 40 mg / kg administration Group (ischemia-reperfusion / fidarestat 40 mg / kg administration group), and ischemic surgery + fidarestat 150 mg / kg administration group (ischemia reperfusion / fidarestat 150 mg / kg G). Fidarestat at 40 or 150 mg / kg / day was mixed into their feed and administered to the ischemic surgery + fidarestat administration group 7 days before the ischemic surgery.

[0033] Under isoflurane anesthesia, a laser blood flow meter was used to measure the plantar blood flow in these mice, and then the abdomen was incised. Expose the abdomi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The objective of the invention is to provide an agent for prevention and treatment of acute renal failure which is caused by the following lasting or aggravated diseases: systemic inflammatory response syndrome caused by trauma, burn, pancreatitis, septicemia or infection; DIC syndrome; multiple organ failure; peripheral arterial occlusive disease; occlusive atherosclerosis; and crush syndrome; or post-transplantation complication. The invention is an agent for prevention and treatment of acute renal failure, which contains a hydantoin derivative represented by the general formula below as an active ingredient. Among such compounds, (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide is particularly preferable. (Formula) (In the formula, X represents a halogen atom or a hydrogen atom, and R<1> and R<2> independently represent a hydrogen atom or an optionally substituted C1-6 alkyl group, or R<1> and R<2> are combined with nitrogen atom to which R<1> and R<2> are connected or optionally another nitrogen atom or oxygen atom to form 5- and 6-membered heterocycle.

Description

Technical field [0001] The present invention relates to a new medicinal use of hydantoin derivatives known as ARI. Background of the invention [0002] Systemic inflammatory response syndrome caused by trauma, burns, pancreatitis, sepsis, or infection; diffuse intravascular coagulation syndrome; multiple organ failure; peripheral arterial occlusive disease; arteriosclerosis obliterans; and crush syndrome as inflammation Sexual diseases, and ischemic circulatory failure are caused by the persistence or aggravation of inflammatory cytokines. As a result, damage to important organs and tissue damage occurred, which caused acute renal failure. That is, the above-mentioned diseases are related to vital prognosis, and at present, they significantly impair the quality of life of patients and fear that they are diseases showing high mortality. With reference to the treatment of diseases with increasing severity, high-dose steroid therapy for the purpose of suppressing the production of i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4188A61P13/12C07D491/107
CPCA61K31/4188C07D491/10A61P13/12A61P9/10C07D491/107
Inventor 八木桥操六小笠原早织日比千寻加藤宪明
Owner SANWAKAGUKU KENKYUSHO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com